Overview

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Eligibility

Inclusion Criteria:

• Non-squamous NSCLC, not amenable to treatment in curative intent.
• Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).
• Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting.
• Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed).

Exclusion criteria:

• Inadequate organ function and/or bone marrow reserve.
• Leptomeningeal metastases or spinal cord compression.
• Poorly controlled systemic medical conditions.
• Other protocol-defined inclusion/exclusion criteria apply.